Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair?

Translational Research

Volumn 154, Issue 2, 2009, Pages 61-69

  Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTERFERON; AUTOANTIBODY; CELL ADHESION MOLECULE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY COMPLEX; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; HEMANGIOMA; HUMAN; METABOLIC DISORDER; NEOPLASM; NONHUMAN; OSTEOCLASTOMA; POPULATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 67649874758     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.05.005     Document Type: Review

References (106)

1. Herrmann M., Voll R.E., and Kalden J.R. Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21 (2000) 424-426
2. Tang S., Lui S.L., and Lai K.N. Pathogenesis of lupus nephritis: an update. Nephrology 10 (2005) 174-179
3. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 (1997) 408-415
4. Aranow C., and Ginzler E.M. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 9 (2000) 166-169
5. Manzi S., Selzer F., Sutton-Tyrrell K., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42 (1999) 51-60
6. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42 (1999) 338-346
7. Bacon P.A., Stevens R.J., Carruthers D.M., Young S.P., and Kitas G.D. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1 (2002) 338-347
8. Esdaile J.M., Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001) 2331-2337
9. Anderson T.J., Gerhard M.D., Meredith I.T., et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 75 (1995) 71B-74B
10. Rajagopalan S., Somers E.C., Brook R.D., et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103 (2004) 3677-3683
11. Bruce I.N., Gladman D.D., Ibanez D., and Urowitz M.B. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. J Rheumatol 30 (2003) 288-291
12. Pieretti J., Roman M.J., Devereux R.B., et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 116 (2007) 419-426
13. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2399-2406
14. Roman M.J., Crow M.K., Lockshin M.D., et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 56 (2007) 3412-3419
15. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2407-2415
16. Thompson T., Sutton-Tyrrell K., Wildman R.P., et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 58 (2008) 835-842
17. Kao A.H., Wasko M.C., Krishnaswami S., et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol 102 (2008) 755-760
18. Rhew E.Y., Manzi S.M., Dyer A.R., et al. Differences in subclinical cardiovascular disease between African American and Caucasian women with systemic lupus erythematosus. Transl Res 153 (2009) 51-59
19. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
20. Maradit-Kremers H., Crowson C.S., Nicola P.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52 (2005) 402-411
21. Sitia S., Atzeni F., Sarzi-Puttini P., et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 8 (2009) 281-286
22. Margutti P., Matarrese P., Conti F., et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 111 (2008) 4559-4570
23. Belizna C.C., Richard V., Thuillez C., Levesque H., and Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 7 (2007) 46-51
24. Gresele P., Migliacci R., Vedovati M.C., et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 123 (2009) 444-451
25. Bilora F., and Sartori M. Flow-mediated arterial dilation in primary antiphospholipid syndrome. Angiology 60 (2009) 104
26. Der H., Kerekes G., Veres K., et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16 (2007) 497-503
27. Farzaneh-Far A., Roman M.J., Lockshin M.D., et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 54 (2006) 3918-3925
28. Meroni P.L., Peyvandi F., Foco L., et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 5 (2007) 2421-2428
29. Ansari A., Larson P.H., and Bates H.D. Vascular manifestations of systemic lupus erythematosus. Angiology 37 (1986) 423-432
30. Rho Y.H., Chung C.P., Oeser A., et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 35 (2008) 1789-1794
31. Chung C.P., Avalos I., Oeser A., et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66 (2007) 208-214
32. McMahon M., Grossman J., FitzGerald J., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54 (2006) 2541-2549
33. Chung C.P., Oeser A., Solus J.F., et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58 (2008) 2105-2112
34. Von Feldt J.M., Scalzi L.V., Cucchiara A.J., et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 54 (2006) 2220-2227
35. Reichlin M., Fesmire J., Quintero-Del-Rio A.I., and Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2957-2963
36. de Carvalho J.F., Borba E.F., Viana V.S., Bueno C., Leon E.P., and Bonfa E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?. Arthritis Rheum 50 (2004) 3610-3615
37. Borba E.F., Bonfa E., Vinagre C.G., Ramires J.A., and Maranhao R.C. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43 (2000) 1033-1040
38. Denny M.F., Thacker S., Mehta H., et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110 (2007) 2907-2915
39. Asai K., Kudej R.K., Shen Y.T., et al. Peripheral vascular endothelial dysfunction and apoptosis in old monkeys. Arterioscler Thromb Vasc Biol 20 (2000) 1493-1499
40. Choy J.C., Granville D.J., Hunt D.W., and McManus B.M. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33 (2001) 1673-1690
41. Bombeli T., Karsan A., Tait J.F., and Harlan J.M. Apoptotic vascular endothelial cells become procoagulant. Blood 89 (1997) 2429-2442
42. Tedgui A., and Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb Haemost 86 (2001) 420-426
43. Diamant M., Nieuwland R., Pablo R.F., Sturk A., Smit J.W., and Radder J.K. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 106 (2002) 2442-2447
44. Dimmeler S., Hermann C., and Zeiher A.M. Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?. Eur Cytokine Netw 9 (1998) 697-698
45. Dimmeler S., and Zeiher A.M. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res 87 (2000) 434-439
46. Mallat Z., Benamer H., Hugel B., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101 (2000) 841-843
47. Mallat Z., and Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 88 (2001) 998-1003
48. Hafezi-Moghadam A., Simoncini T., Yang E., et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8 (2002) 473-479
49. George J., Herz I., Goldstein E., et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 23 (2003) e57-e60
50. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) E1-E7
51. Werner N., and Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?. Arterioscler Thromb Vasc Biol 26 (2006) 257-266
52. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
53. Chironi G., Walch L., Pernollet M.G., et al. Decreased number of circulating CD34(+)KDR(+) cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis 191 (2006) 115-120
54. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
55. Schmidt-Lucke C., Rossig L., Fichtlscherer S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111 (2005) 2981-2987
56. Moldovan L., and Moldovan N.I. Role of monocytes and macrophages in angiogenesis. Exs (2005) 127-146
57. Kaplan M.J., Lewis E.E., Shelden E.A., et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 169 (2002) 6020-6029
58. Bell D.A., and Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin Immunol Immunopathol 60 (1991) 13-26
59. Emlen W., Niebur J., and Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152 (1994) 3685-3692
60. Clancy R.M. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr Rheumatol Rep 2 (2000) 39-43
61. Dignat-George F., and Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol 65 (2000) 215-220
62. Woywodt A., Streiber F., de Groot K., Regelsberger H., Haller H., and Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361 (2003) 206-210
63. Moonen J.R., de Leeuw K., van Seijen X.J., et al. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther 9 (2007) R84
64. Westerweel P.E., Luijten R.K., Hoefer I.E., Koomans H.A., Derksen R.H., and Verhaar M.C. Haematopoietic and endothelial progenitor cells are deficient in quiescent Systemic Lupus Erythematosus. Ann Rheum Dis 66 (2007) 865-870
65. Lee P.Y., Li Y., Richards H.B., et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 56 (2007) 3759-3769
66. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
67. Crow M.K., and Kirou K.A. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 16 (2004) 541-547
68. Crow M.K., and Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 5 (2003) 279-287
69. Kirou K.A., Lee C., George S., et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3958-3967
70. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., and Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52 (2005) 1491-1503
71. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 19795;301:5-8
72. Lovgren T., Eloranta M.L., Bave U., Alm G.V., and Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 50 (2004) 1861-1872
73. Dall'era M.C., Cardarelli P.M., Preston B.T., Witte A., and Davis Jr. J.C. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 64 (2005) 1692-1697
74. Pannetier D., Faure C., Georges-Courbot M.C., Deubel V., and Baize S. Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. J Virol 78 (2004) 10516-10524
75. Majka M., Janowska-Wieczorek A., Ratajczak J., et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 97 (2001) 3075-3085
76. Banchereau J., and Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (2006) 383-392
77. Albini A., Marchisone C., Del Grosso F., et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 156 (2000) 1381-1393
78. Slaton J.W., Perrotte P., Inoue K., Dinney C.P., and Fidler I.J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 2726-2734
79. Oliveira I.C., Sciavolino P.J., Lee T.H., and Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci U S A 89 (1992) 9049-9053
80. Borden E.C. Review: Milstein Award lecture: interferons and cancer: where from here?. J Interferon Cytokine Res 25 (2005) 511-527
81. Leibovitch I., Loewenstein A., Alster Y., et al. Interferon alpha-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. Ophthalmic Surg Lasers Imaging 35 (2004) 16-22
82. Ezekowitz R.A., Mulliken J.B., and Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326 (1992) 1456-1463
83. Kaban L.B., Mulliken J.B., Ezekowitz R.A., Ebb D., Smith P.S., and Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 103 (1999) 1145-1149
84. Thacker S., Duquaine D., Park J., and Kaplan M.J. Lupus prone mice display endothelial dysfunction and abnormal vascular repair. Arthritis Rheum (2008) 58
85. Kim D., Peck A., Santer D., et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 58 (2008) 2163-2173
86. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., and Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 56 (2007) 3995-4004
87. Yao Y., Richman L., Morehouse C., et al. Type I interferon: potential therapeutic target for psoriasis?. PLoS ONE 3 (2008) e2737
88. Vaudo G., Bocci E.B., Shoenfeld Y., et al. Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis Rheum 52 (2005) 3890-3897
89. Davis III J.M., Roger V.L., Crowson C.S., Kremers H.M., Therneau T.M., and Gabriel S.E. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 58 (2008) 2603-2611
90. Hermann F., Forster A., Chenevard R., Enseleit F., Hurlimann D., Corti R., et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 45 3 (2005) 461-464
91. Ferreira G.A., Navarro T.P., Telles R.W., Andrade L.E., and Sato E.I. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46 10 (2007) 1560-1565
92. Aprahamian T., Bonegio R.G., Richez C., Yasuda K., Chiang L.K., Sato K., et al. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 182 1 (2009) 340-346
93. Zhao W., Thacker S., Hodgin J.B., Zhang H., Wang J.H., Park J.L., et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone improves ardiometabolic risk and renal inflammation in murine lupus. J Immunol (2009) (in press)
94. Alarcon G.S., McGwin G., Bertoli A.M., et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66 (2007) 1168-1172
95. Sachet J.C., Borba E.F., Bonfa E., Vinagre C.G., Silva V.M., and Maranhao R.C. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 16 (2007) 273-278
96. Wasko M.C., Hubert H.B., Lingala V.B., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298 (2007) 187-193
97. Lund J.M., Alexopoulou L., Sato A., et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101 (2004) 5598-5603
98. Laurent A.F., Dumont S., Poindron P., and Muller C.D. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 24 (1996) 59-67
99. Blaheta R.A., Leckel K., Wittig B., et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transplant Immunol 6 (1998) 251-259
100. Shimizu H., Takahashi M., Takeda S., et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 77 (2004) 1661-1667
101. Nagy S.E., Andersson J.P., and Andersson U.G. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines. Immunopharmacology 26 (1993) 11-20
102. Gibson W.T., and Hayden M.R. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann NY Acad Sci 1110 (2007) 209-221
103. Nashel D.J. Is atherosclerosis a complication of long-term corticosteroid treatment?. Am J Med 80 (1986) 925-929
104. Bennett L., Palucka A.K., Arce E., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197 (2003) 711-723
105. Panoulas V.F., Douglas K.M., Stavropoulos-Kalinoglou A., et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology 47 (2008) 72-75
106. Boers M., Nurmohamed M.T., Doelman C.J., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 842-845